Skip to main content
Sign In

David Raben, MD


David Raben, MD

Interests: Head and Neck Cancers, GU Cancers and Lung Cancer​

David Raben, M.D. is currently faculty at the University of Colorado where he is a board-certified Professor of Radiation Oncology and has recently been named a U.S. News Top Doctor. He has also previously been voted a Top Doctor in 5280 magazine. He received a B.A. in Psychology from Duke University in 1985 and then completed his M.D. at Wake Forest University/Bowman Grey School of Medicine in 1990. After graduation, he did his internship at the University of Hawaii and residency in Radiation Oncology at the Johns Hopkins Hospital from 1991-1994, serving as a chief resident in 1994. He took his initial faculty position at the University of Alabama at Birmingham from 1994-1998 heading the GI tumor working group and receiving a prestigious American Cancer Society translational oncology grant to study brain tumors. 

From a clinical perspective, Dr. Raben has developed nationally recognized clinical expertise over the past 20 years in the management of head and neck cancer (HNC), lung cancer and prostate/bladder cancers. He was the first to introduce intensity modulated radiation techniques for HNC and the first to spare the critical salivary glands and thyroid glands for patients undergoing radiation. For prostate cancer Dr. Raben first introduced accelerated hypofractionated radiation to the prostate while simultaneously treating the lymph nodes in the Rocky Mountain region, shortening overall treatment time to 5.5 weeks from 8.5 weeks with no increase in long term side effects and excellent outcomes. Dr. Raben has extensive experience spanning over 20 years with low (LDR) and high dose rate (HDR) brachytherapy for prostate cancer.

From a research perspective, his focus has been on laboratory discoveries and innovative clinical trials only offered at UCHealth in areas such as high risk, heavy smoker HNC patients and offer approaches that will inhibit cancer DNA repair. Dr. Raben recently completed the first Phase I clinical trial in the US with and oral DNA repair inhibitor (PARP inhibitor) and radiation for heavy smokers when combined with intensity modulated radiation (IMRT). He was a major contributor of the clinical design and implementation of a trial combing a biologic drug against growth factors with radiation that led to FDA approval of the drug called Erbitux.

From a national perspective, Dr. Raben is honored to serve on the NRG Oncology head and neck steering committee. In addition, he served on the planning committees for the ASTRO HNC Symposiums and was the chair and past chair for the 2014 and 2016 meetings. Dr. Raben is a member of the American Head and Neck Society and recently served on the steering committee for the 2017 6th International Congress of Head and Neck Oncology held in Barcelona, Spain. Dr. Raben is also a steering committee member of the GU section of the Southwest Oncology Group. He actively serves as an ASCO Ambassador for Multidisciplinary Cancer Management Courses (MCMC) to help educate underserved areas around the world in cancer care. Finally, he serves as the Developmental Therapeutics Co-Chair at the NRG. He is an ad hoc reviewer for high impact journals such as Journal of Clinical Oncology, JAMA Oncology, Oral Oncology, Head and Neck, Int. Journal of Radiation Oncology Biology Physics, Clinical Cancer Research and Cancer Research. He has authored over 140 publications with several additional manuscripts in review. 


Click here to see Dr. Raben's PubMed Page